-
Mashup Score: 0
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
Ph3 Len +/- Ixa maintenance for MRD+ s/p ASCT -> #EAOnc EAA171 - Optimizing Prolonged Treatment In Myeloma Using MRD assessment (OPTIMUM) [Activation: Jun 1, 2021] https://t.co/4TRHkoLObg PI= @myelomaMD #NCT03941860 @eaonc #mmMRD #mmsm #bmtsm n=510 https://t.co/nqgonvFmC4